Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QAW039 add-on therapy for uncontrolled severe asthma
MOH_2017-03-13_000124Phase 3Completed
- Sponsor
- Novartis
- Start
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fevipiprant in asthma and severe asthma (3 arms), sponsored by Novartis. Primary endpoint: Rate of moderate-to-severe asthma exacerbations. Started May 2016; status: completed.
02
Drugs
fevipiprant
03
Conditions
asthmasevere asthma
Beyond the preview
Go deeper on MOH_2017-03-13_000124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-03-13_000124.